Shanghai Fosun Pharmaceutical (Group) Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Shanghai Fosun Pharmaceutical (Group) de 22% y 9.3% por año respectivamente. Se prevé que el BPA crezca en un 22.4% al año. Se espera que la rentabilidad financiera sea de 8.8% en 3 años.

Información clave

22.0%

Tasa de crecimiento de los beneficios

22.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.1%
Tasa de crecimiento de los ingresos	9.3%
Rentabilidad financiera futura	8.8%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26

Previsiones de crecimiento de beneficios e ingresos

SHSE:600196 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	54,047	4,605	1,662	5,119	4
12/31/2025	50,804	4,279	1,537	4,384	8
12/31/2024	45,054	3,342	4,645	4,769	7
12/31/2023	41,400	2,386	-1,922	3,414	N/A
9/30/2023	43,029	3,578	-2,095	3,535	N/A
6/30/2023	43,999	3,972	-2,007	4,229	N/A
3/31/2023	44,437	4,261	-1,858	4,235	N/A
12/31/2022	43,952	3,731	-1,671	4,218	N/A
9/30/2022	43,586	3,600	-1,882	4,066	N/A
6/30/2022	43,406	3,782	-1,252	4,030	N/A
3/31/2022	41,340	4,338	-1,140	4,057	N/A
12/31/2021	39,011	4,729	-1,035	3,938	N/A
9/30/2021	35,253	4,749	-1,525	3,142	N/A
6/30/2021	33,231	4,430	-1,994	2,825	N/A
3/31/2021	32,483	3,933	-1,748	2,934	N/A
12/31/2020	30,307	3,663	-1,857	2,580	N/A
9/30/2020	29,460	3,737	-1,021	3,347	N/A
6/30/2020	28,441	3,520	-592	3,234	N/A
3/31/2020	27,736	3,187	-552	3,197	N/A
12/31/2019	28,585	3,322	-740	3,222	N/A
9/30/2019	28,004	2,677	-449	3,191	N/A
6/30/2019	27,232	2,664	-893	3,122	N/A
3/31/2019	25,929	2,714	-875	2,892	N/A
12/31/2018	24,918	2,708	-225	2,950	N/A
9/30/2018	23,716	2,799	-55	2,945	N/A
6/30/2018	22,040	2,996	287	2,755	N/A
3/31/2018	20,372	3,092	224	2,644	N/A
12/31/2017	18,534	3,124	410	2,580	N/A
9/30/2017	16,951	3,047	N/A	2,310	N/A
6/30/2017	16,045	2,993	N/A	2,278	N/A
3/31/2017	15,283	2,908	N/A	2,128	N/A
12/31/2016	14,629	2,805	N/A	2,110	N/A
9/30/2016	14,173	2,745	N/A	1,983	N/A
6/30/2016	13,624	2,657	N/A	1,880	N/A
3/31/2016	13,034	2,557	N/A	1,822	N/A
12/31/2015	12,609	2,459	N/A	1,621	N/A
9/30/2015	12,438	2,429	N/A	1,519	N/A
6/30/2015	12,408	2,398	N/A	1,474	N/A
3/31/2015	12,168	2,234	N/A	1,376	N/A
12/31/2014	12,026	2,113	N/A	1,200	N/A
9/30/2014	11,587	2,207	N/A	1,388	N/A
6/30/2014	11,026	1,987	N/A	1,104	N/A
3/31/2014	10,598	1,646	N/A	942	N/A
12/31/2013	9,996	1,583	N/A	1,012	N/A
9/30/2013	9,024	1,421	N/A	717	N/A
6/30/2013	8,356	1,475	N/A	746	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (22% al año) de 600196 es superior a la tasa de ahorro (2.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (22% al año) de 600196 crezcan menos que el mercado CN (24% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 600196 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (9.3% al año) de 600196 crezcan más despacio que el mercado de CN (14.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.3% al año) de 600196 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 600196 sea baja dentro de 3 años (8.8%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Shanghai Fosun Pharmaceutical (Group) Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 17%

Price target decreased by 13% to CN¥32.65

Price target decreased by 7.0% to CN¥37.41

Consensus forecasts updated

Price target decreased to CN¥46.32

Price target decreased to CN¥50.41

Recent updates

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Consensus EPS estimates fall by 17%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Profit margin trend

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Price target decreased by 13% to CN¥32.65

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Price target decreased by 7.0% to CN¥37.41

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Third quarter 2022 earnings: Revenues exceed analyst expectations

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Executive Vice Chairman recently bought CN¥391k worth of stock

Now 20% undervalued after recent price drop

Executive Chairman recently bought CN¥887k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Price target decreased to CN¥46.32

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥50.41

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥56.55

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022

Price target decreased to CN¥56.55

Price target decreased to CN¥58.66

Investor sentiment improved over the past week

Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Investor sentiment deteriorated over the past week

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Third quarter 2021 earnings released: EPS CN¥0.42 (vs CN¥0.30 in 3Q 2020)

Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion.

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.43 in 2Q 2020)

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Price target increased to CN¥65.58

Price target increased to CN¥64.03

Investor sentiment deteriorated over the past week

Price target increased to CN¥57.92